Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects.
Low Confidence In VitroPrimary source: [Open]
Linked compounds: retatrutide
Outcomes summary
Medicinal chemistry and pharmacology study describing design of triple GLP-1R/GCGR/GIPR agonists with varied receptor potency profiles, providing mechanistic context for triple-agonist approaches in metabolic disease.
Limitations
Preclinical/mechanistic focus; not a clinical outcomes study and may not generalize across all triple-agonist molecules.
Notes
Primary source: PMID 40958513 (see PubMed link on this page).